TY - PAT
T1 - Selective Neural Nitric Oxide Synthase Inhibitors
AU - Silverman, Richard
N1 - filingdate: 2002-6-24
issueddate: 2004-10-12
Status: published
attorneydocketnumber: 2001-036-02
PY - 2004/10/12
Y1 - 2004/10/12
N2 - Novel Peptide Compounds with Selective Inhibition of Neuronal Nitric Oxide Synthase
NU2001-036
Inventors
Jung-Mi Hah
Richard Silverman*
Short Description
Synthesis of a series of compounds with selective inhibition of neuronal nitric oxide synthase (nNOS)
Abstract
Northwestern researchers have isolated and identified a series of compounds that have significant implications in the treatment of neurological diseases. The family of NOS enzymes, of which there are three principal isoforms, biosynthesize an important biological second messenger called nitric oxide. While inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) are crucial for maintaining body function, the activity of neuronal nitric oxide synthase (nNOS) has become a desired target for control as its overexpression has been implicated in various neurological diseases and neuronal damage. The inhibitory peptides described here demonstrate very high selectivity for inhibition of neuronal nitric oxide synthase over inducible nitric oxide synthase (iNOS) and/or endothelial nitric oxide synthase (eNOS). The novel compounds provide promising solutions for the long-term management of neurological diseased states associated with excess nNOS formation.
Applications
Therapeutics for neurological disorders:
Stroke, Schizophrenia, Migraine Headaches, Cerebral Ischemia, Long-Term Depression, Parkinson's disease and Alzheimer's disease
Advantages
Selective modulation of nitric oxide synthesis
Long-term management of neurological disorders
IP Status
Issued U.S. Patent No. 6,803,486
Issued U.S. Patent No. 6,274,557
Issued U.S. Patent No. 7,470,815
Contact Information
Allan Nader, PhD
Invention Manager
(p) (847) 491-4456
(e) [email protected]
AB - Novel Peptide Compounds with Selective Inhibition of Neuronal Nitric Oxide Synthase
NU2001-036
Inventors
Jung-Mi Hah
Richard Silverman*
Short Description
Synthesis of a series of compounds with selective inhibition of neuronal nitric oxide synthase (nNOS)
Abstract
Northwestern researchers have isolated and identified a series of compounds that have significant implications in the treatment of neurological diseases. The family of NOS enzymes, of which there are three principal isoforms, biosynthesize an important biological second messenger called nitric oxide. While inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) are crucial for maintaining body function, the activity of neuronal nitric oxide synthase (nNOS) has become a desired target for control as its overexpression has been implicated in various neurological diseases and neuronal damage. The inhibitory peptides described here demonstrate very high selectivity for inhibition of neuronal nitric oxide synthase over inducible nitric oxide synthase (iNOS) and/or endothelial nitric oxide synthase (eNOS). The novel compounds provide promising solutions for the long-term management of neurological diseased states associated with excess nNOS formation.
Applications
Therapeutics for neurological disorders:
Stroke, Schizophrenia, Migraine Headaches, Cerebral Ischemia, Long-Term Depression, Parkinson's disease and Alzheimer's disease
Advantages
Selective modulation of nitric oxide synthesis
Long-term management of neurological disorders
IP Status
Issued U.S. Patent No. 6,803,486
Issued U.S. Patent No. 6,274,557
Issued U.S. Patent No. 7,470,815
Contact Information
Allan Nader, PhD
Invention Manager
(p) (847) 491-4456
(e) [email protected]
M3 - Patent
M1 - 6803486
ER -